Template bleeding time and PFA‐100® have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients

Schafer, 1994, Approach to bleeding, 407 Quiroga, 1997, Skin and mucous membrane hemorrhages: clinical assessment, study sequence and relative frequency of hereditary diseases of the hemostasis in a Chilean population, Rev Med Chil, 125, 409 Posan, 2003, Comparison of PFA‐100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice, Thromb Haemost, 90, 483, 10.1160/TH03-01-0004 Burns, 1989, Bleeding time. A guide to its diagnostic and clinical utility, Arch Pathol Lab Med, 113, 1219 Rodgers, 1990, A critical reappraisal of the bleeding time, Sem Thromb Haemost, 16, 1, 10.1055/s-2007-1002658 Lind, 1991, The bleeding time does not predict clinical bleeding, Blood, 77, 2547, 10.1182/blood.V77.12.2547.2547 Triplett, 1989, The bleeding time. Neither pariah or panacea, Arch Pathol Lab Med, 113, 1207 Fressinaud, 1998, Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases, Blood, 91, 1325, 10.1182/blood.V91.4.1325 Cattaneo, 1999, Evaluation of the PFA‐100® system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease, Thromb Haemost, 82, 35, 10.1055/s-0037-1614626 Dean, 2000, Von Willebrand disease in a pediatric‐based population—comparison of type 1 diagnostic criteria and use of the PFA‐100® and a von Willebrand factor/collagen binding assay, Thromb Haemost, 84, 401, 10.1055/s-0037-1614035 Schlammadinger, 2000, Comparison of the O'Brien filter test and the PFA‐100 platelet analyzer in the laboratory diagnosis of von Willebrand's disease, Thromb Haemost, 84, 88, 10.1055/s-0037-1613973 Favaloro, 2001, Laboratory diagnosis of von Willebrand disorder (VWD) and monitoring of DDAVP therapy: efficacy of the PFA‐100® and VWF. CBA as combined diagnostic strategies, Haemophilia, 7, 180, 10.1046/j.1365-2516.2001.00487.x Favaloro, 2002, Clinical application of the PFA‐100®, Curr Opin Hematol, 9, 407, 10.1097/00062752-200209000-00004 Cattaneo, 1999, Evaluation of platelet function with the PFA‐100® system in patients with congenital defects of platelet secretion, Thromb Res, 96, 213, 10.1016/S0049-3848(99)00102-4 Kerényi, 1999, Comparison of PFA‐100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function, Thromb Res, 96, 487, 10.1016/S0049-3848(99)00152-8 Cattaneo, 2003, Inherited platelet‐based bleeding disorders, J Thromb Haemost, 1, 1628, 10.1046/j.1538-7836.2003.00266.x Langdell, 1953, Effect of antihemophilic factor on one‐stage clotting tests, J Lab Clin Med, 41, 637 Allain, 1975, Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor, J Lab Clin Med, 85, 318 Siekmann, 1998, The determination of von Willebrand factor activity by collagen binding assay, Haemophilia, 4, 15, 10.1046/j.1365-2516.1998.0040s3015.x Budde, 1990, Luminographic detection of von Willebrand factor multimers in agarose gels and on nitrocellulose membranes, Thromb Haemost, 63, 312, 10.1055/s-0038-1645215 Quiroga, 1994, Sex‐related difference in plasma von Willebrand factor (VWF:Ag and VWF:RiCof) levels in adolescents, Thromb Haemost, 71, 800, 10.1055/s-0038-1642529 Mezzano, 1996, Hemostatic disorder of uremia: the platelet defect, main determinant of the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis, Thromb Haemost, 76, 312, 10.1055/s-0038-1650576 Kumar, 1990, A modified HPLC technique for simultaneous measurement of 5‐hydroxytryptamine and 5‐hydroxyindoleacetic acid in cerebrospinal fluid, platelet and plasma., Life Sci, 47, 1751, 10.1016/0024-3205(90)90349-V Favaloro, 2001, Utility of the PFA‐100® for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations, Haemophilia, 7, 170, 10.1046/j.1365-2516.2001.00486.x Nosek‐Cenkowska, 1991, Bleeding/bruising symtomatology in children with and without bleeding disorders, Thromb Haemost, 65, 237, 10.1055/s-0038-1647491 Mauser Bunschoten, 1988, Bleeding symptoms in carriers of haemophilia A and B, Thromb Haemost, 59, 349, 10.1055/s-0038-1647493 Wuillemin, 2002, Evaluation of a platelet function analyzer (PFA‐100®) in patients with a bleeding tendency, Swiss Med Wkly, 132, 443 Gerrard, 1992, A role for prostacyclin in bruising symptomatology, Pediatrics, 90, 33, 10.1542/peds.90.1.33 Simon, 1995, Effects of nitric oxide synthase inhibition on bleeding time in humans, J Cardiovasc Pharmacol, 26, 339, 10.1097/00005344-199508000-00022 Ubatuba, 1979, The effect of prostacyclin (PGI2) on platelet behaviour. Thrombus formationin vivoand bleeding time, Thromb Haemost, 23, 425